^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L861Q

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    U31402-A-U102: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=312, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X • KRAS G12
    |
    patritumab deruxtecan (U3-1402)
    2d
    EAY131-A: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR L861Q • EGFR S768I
    |
    Gilotrif (afatinib)
    2d
    EAY131-E: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR L861Q
    |
    Tagrisso (osimertinib)
    9d
    D516KC00001: A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib (2024-511362-37-00)
    P2/3, N=200, Recruiting, AstraZeneca AB | Active, not recruiting --> Recruiting
    Enrollment open
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    17d
    TAS6417-302: Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery (2025-521775-31-00)
    P2/3, N=131, Recruiting, Taiho Oncology Inc.
    New P2/3 trial
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • zipalertinib (CLN-081)
    22d
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    25d
    An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=59, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • itacitinib (INCB039110)
    26d
    REZILIENT2: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (clinicaltrials.gov)
    P2, N=324, Recruiting, Taiho Oncology, Inc. | N=224 --> 324 | Trial completion date: Aug 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    zipalertinib (CLN-081)
    29d
    Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2029 --> Jun 2030 | Initiation date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2028 --> Jun 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    EGFR mutation • EGFR L861Q • EGFR G719X
    |
    carboplatin • pemetrexed • zipalertinib (CLN-081)
    1m
    Adjuvant icotinib and osimertinib in the treatment of EGFR-mutated resectable non-small cell lung cancer: A real-world multicenter cohort study in China (ChiCTR2500112843)
    P=N/A, N=200, Not yet recruiting, Beijing Chest Hospital Capital Medical University; Beijing Chest Hospital Capital Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • Conmana (icotinib) • simmitinib (SYHA1817)
    1m
    A prospective clinical study on the efficacy and safety of Limerinib Tablets in the treatment of local advanced or recurrent metastasis of EGFR mutation with meningeal metastasis and non-scaly NSCLC (ChiCTR2500111717)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    1m
    Limertinib Plus Platinum-Based Chemotherapy in Patients with Advanced EGFR-Mutated Non-Squamous NSCLC after Progression on First-Line EGFR-TKI Therapy : A Single-Arm, Multicenter Study (ChiCTR2500114831)
    P2, N=61, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New P2 trial
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • limertinib (ASK120067)